Biotech Values

[dav1234]

Revance proving volatile
Revance (RVNC) continues its volatile ways following its IPO on February 6, when it debuted at $16. The stock is up 2.5% today at $27.61 but that's down sharply from earlier highs and follows a steep fall at the end of last week.
Revance's lead product is a topical Botulinum Toxin Type A Gel for the treatment of lateral canthal lines (crow's feet). It will complete with Allergan's (AGN) blockbuster injectable treatment Botox.
Botulinum is in Phase 3 trials in the U.S.
Anaylsts' price targets range from $37-55.



http://www.analystratings.net/stocks/NASDAQ/RVNC/?RegistrationCode=SocialMedia-direct